Cargando…

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis

Venetoclax plus cytarabine therapy is approved for elderly acute myeloid leukemia (AML) patients and needs further improvement. We studied the mechanisms of venetoclax plus cytarabine treatment and searched for a third agent to enhance their effects. Cytarabine induces S phase arrest-mediated DNA da...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jingyi, Wang, Yuetong, Yin, Chujie, Gong, Ping, Zhang, Zhenwei, Zhao, Linxiang, Waxman, Samuel, Jing, Yongkui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021233/ https://www.ncbi.nlm.nih.gov/pubmed/35443722 http://dx.doi.org/10.1038/s41419-022-04810-z

Ejemplares similares

The NOXA–MCL1–BIM axis defines lifespan on extended mitotic arrest
por: Haschka, Manuel D., et al.
Publicado: (2015)

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
por: Weller, Sandra, et al.
Publicado: (2022)

Roscovitine-induced Apoptosis in Neutrophils and Neutrophil Progenitors Is Regulated by the Bcl-2-Family Members Bim, Puma, Noxa and Mcl-1
por: Gautam, Sanjivan, et al.
Publicado: (2013)

The role of VDR and BIM in potentiation of cytarabine–induced cell death in human AML blasts
por: Harrison, Jonathan S., et al.
Publicado: (2016)

Correction: Roscovitine-induced Apoptosis in Neutrophils and Neutrophil Progenitors Is Regulated by the Bcl-2-Family Members Bim, Puma, Noxa and Mcl-1
por: Gautam, Sanjivan, et al.
Publicado: (2014)

Dihydroartemisinin and its derivative induce apoptosis in acute myeloid leukemia through Noxa-mediated pathway requiring iron and endoperoxide moiety
por: Zhao, Xuan, et al.
Publicado: (2015)

Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51
por: Xie, Chengzhi, et al.
Publicado: (2013)

Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis
por: Tomic, Barbara, et al.
Publicado: (2022)

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML
por: Luo, Xiao-Hua, et al.
Publicado: (2023)

The role of glucocorticoid receptor phosphorylation in Mcl-1 and NOXA gene expression
por: Lynch, James T, et al.
Publicado: (2010)

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM
por: Huemer, Florian, et al.
Publicado: (2019)

Expression of Bim, Noxa, and Puma in non-small cell lung cancer
por: Sakakibara-Konishi, Jun, et al.
Publicado: (2012)

BIM and NOXA are mitochondrial effectors of TAF6δ-driven apoptosis
por: Delannoy, Aurélie, et al.
Publicado: (2018)

DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complex
por: Nakajima, Wataru, et al.
Publicado: (2016)

Cytarabine/venetoclax: Recurrent Corynebacterium bacteraemia: case report
Publicado: (2022)

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax
por: Fooks, Katie, et al.
Publicado: (2022)

The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin
por: Geserick, P, et al.
Publicado: (2014)

The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin
por: Geserick, P, et al.
Publicado: (2015)

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms
por: Nguyen, Tri, et al.
Publicado: (2018)

MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1:NOXA complex
por: Djajawi, Tirta Mario, et al.
Publicado: (2020)

Apoptosis induced by overall metabolic stress converges on the Bcl-2 family proteins Noxa and Mcl-1
por: Wensveen, Felix M., et al.
Publicado: (2011)

MARCH5-dependent degradation of MCL1/NOXA complexes defines susceptibility to antimitotic drug treatment
por: Haschka, Manuel D., et al.
Publicado: (2020)

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
por: Malani, D, et al.
Publicado: (2017)

Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia
por: Cojocari, Dan, et al.
Publicado: (2021)

PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
por: Minarik, L., et al.
Publicado: (2022)

BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells
por: Sharma, A, et al.
Publicado: (2013)

Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer
por: Nakajima, W, et al.
Publicado: (2014)

AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA
por: Mallick, David J., et al.
Publicado: (2020)

LiCl induces apoptosis via CHOP/NOXA/Mcl-1 axis in human choroidal melanoma cells
por: Zhang, Qiuqiu, et al.
Publicado: (2021)

Cyclic Marinopyrrole Derivatives as Disruptors of Mcl-1 and Bcl-x(L) Binding to Bim
por: Cheng, Chunwei, et al.
Publicado: (2014)

A novel Mcl1 variant inhibits apoptosis via increased Bim sequestration
por: Hagenbuchner, Judith, et al.
Publicado: (2013)

Preferential targeting of MCL-1 by a hydrocarbon-stapled BIM BH3 peptide
por: Hadji, Abbas, et al.
Publicado: (2019)

The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia
por: Di Tullio, Alessandro, et al.
Publicado: (2017)

A novel prohibitin-binding compound induces the mitochondrial apoptotic pathway through NOXA and BIM upregulation
por: Moncunill-Massaguer, Cristina, et al.
Publicado: (2015)

Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021)

A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells
por: Zhao, Tianming, et al.
Publicado: (2023)

Genetic variants of NOXA and MCL1 modify the risk of HPV16-associated squamous cell carcinoma of the head and neck
por: Zhou, Ziyuan, et al.
Publicado: (2012)

Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA
por: Subramanian, Aishwarya, et al.
Publicado: (2016)

MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation
por: Arai, Seiji, et al.
Publicado: (2020)

Down-regulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells
por: Wang, Rui, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9g6hnntn9qsdegp7o1i5sv3o2s